MSI-N -4.74 ULS-N 0.43 CECO-Q 1.64 ELF-N -2.64 NBIS-Q 7.29 RPRX-Q -0.38 CGI-T 0.91
Daily Stock Opinions and Ratings

Latest Stock Buy or Sell? Make More Informed Decisions!

Today, Paul MacDonald and Dennis da Silva commented about whether PXT-T, BNE-T, PONY-T, PDL-T, KEY-T, CVE-T, HBM-T, LUN-T, BTE-T, VET-T, AOT-X, ERF-T, CJ-T, KEL-T, TOU-T, AR-T, BIR-T, ATH-T, TV-T, GTE-T, TOG-T, WCP-T, AGN-N, UNH-N, REGN-Q, MRK-N, SNY-N, SYK-N, AZN-N, TEVA-N, CVS-N, BSX-N, MRK-N, AMGN-Q, ANTM-N, PFE-N, BMY-N, ABBV-N, SNN-N, GILD-Q are stocks to buy or sell.

  • Next Page
WEAK BUY

Sanofi-Aventis(SNY-N)

Jul 17, 2019
It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.
Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$41.570

Stock price when the opinion was issued

Pharma & Healthcare
TOP PICK

Merck & Company(MRK-N)

Jul 17, 2019
A diversified drugmaker that generates consistent returns. Patent declines are offset by a deep pipeline of new drugs from acquisitions. Also boast and organic R&D. MRK pays an attractive yield and has a decent balance sheet. Positive developments continue from Keytruda, an immuno-oncology therapy. MRK trades at 15x earnings. (Analysts’ price target is $91.73)
Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$81.920

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Regeneron Pharmaceuticals Inc(REGN-Q)

Jul 17, 2019
A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials. Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)
Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$299.420

Stock price when the opinion was issued

Pharma & Healthcare
TOP PICK

UnitedHealth Group Inc(UNH-N)

Jul 17, 2019
They report tomorrow. UnitedHealth the largest health insurer in the U.S. It has diversified operations. They acquired of pharmacy benefits manager, Catamaran, that'll give them competitive positioning. No matter who wins the next U.S. election, U.S. healthcare will still need UNH's business. (Analysts’ price target is $291.44)
Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$266.650

Stock price when the opinion was issued

medical services
COMMENT

Allergan PLC.(AGN-N)

Jul 17, 2019
The aesthetics business of this Botox maker account for over 40% of company revenues and this the top player in the business. They also have clinical drugs for application like urinary, psychiatric and migraines.
Paul MacDonaldPaul MacDonald
Unknown
Unlock Rating
$162.460

Stock price when the opinion was issued

Consumer Products
COMMENT

Market Outlook(A Commentary)

Jul 17, 2019
Market Outlook The US-China trade dispute plays a major role in base metals. However, gold has benefited from the uncertainty. He thinks $1500 is possible for gold. The US Fed might look for a 50 point drop within two cuts. This might be an insurance move by the Fed as earnings have been a little less than stellar.
Dennis da SilvaDennis da Silva
Unknown
Unlock Rating
HOLD

Whitecap Resources(WCP-T)

Jul 17, 2019
A darling four years ago, that is oil weighted. The took criticism for the last few acquisitions. He still considers it a core holding and sees a 5% growth outlook along with a 5% yield.
Dennis da SilvaDennis da Silva
Owned
Unlock Rating
$4.170

Stock price when the opinion was issued

Oil and Gas (Integrated Oils)
HOLD

Torc Oil & Gas Ltd(TOG-T)

Jul 17, 2019
An intermediate, oil focused company. Conservative management that under-promises and over delivers. Yield is over 8%. A nice growth profile that is sustainable when WTI is over $50. Their market cap, being only around $1 billion, does limit broader investor interest. A core holding for him.
Dennis da SilvaDennis da Silva
Owned
Unlock Rating
$4.010

Stock price when the opinion was issued

oil gas
COMMENT

Gran Tierra Energy Inc.(GTE-T)

Jul 17, 2019

Gran Tierra (GTE-T) vs Parex Resources (PXT-T). A tale of comparing two brothers. Both are in South America with Columbian core assets. Parex being a pure play vs Gran Tierra having ventured into Peru and Brazil and have exited these areas and now looking at Mexico and so forth. Prefers Parex as a South American play, very consistant. Gran Tierra has had its misteps, still has very good core Columbian assets.

Dennis da SilvaDennis da Silva
Unknown
Unlock Rating
$2.040

Stock price when the opinion was issued

oil gas
DON'T BUY

Trevali Mining Corp(TV-T)

Jul 17, 2019
His single most disappointing holding as a zinc miner. They have great assets -- they are the largest non-senior zinc producer. This is a wait and see turnaround opportunity, so he would look for something else.
Dennis da SilvaDennis da Silva
No
Unlock Rating
$0.265

Stock price when the opinion was issued

Mining
WATCH

Athabasca Oil Sands Corp(ATH-T)

Jul 17, 2019
He does not currently own this. They have a billion dollar joint venture to explore the Duvernay and a similar venture with Statoil and also in thermal development. This may be creating some angst with investors. He is watching this to see how this develops, but is not ready to step in yet.
Dennis da SilvaDennis da Silva
No
Unlock Rating
$0.740

Stock price when the opinion was issued

oil gas
HOLD

Birchcliff Energy Ltd.(BIR-T)

Jul 17, 2019
A premiere gas producer with good critical scale. He owns it, but it will take some patience. It has 20% in liquids and their gas pricing is non-AECO and non-Station 2 (BC), moving into the Chicago market.
Dennis da SilvaDennis da Silva
Owned
Unlock Rating
$2.870

Stock price when the opinion was issued

oil gas
WATCH

Argonaut Gold(AR-T)

Jul 17, 2019
A junior producer in the Americas, within Mexico. A higher cost producer than most that he owns. There are concerns over an Ontario investment they are considering that would require several hundred million dollar capex. It has great NAV leverage to gold price increases.
Dennis da SilvaDennis da Silva
No
Unlock Rating
$2.140

Stock price when the opinion was issued

Mining
PAST TOP PICK

Tourmaline Oil Corp(TOU-T)

Jul 17, 2019
(A Top Pick Sep 28/18, Down 22%) A core holding that is liquids rich as a natural gas producer. The second largest natural gas producer in Canada, producing over 300,000 barrels per day equivalent. They are keeping natural gas production flat, buy growing the liquids output by over 30% this year. This will generate improved cash flow.
Dennis da SilvaDennis da Silva
Owned
Unlock Rating
$17.320

Stock price when the opinion was issued

oil gas
PAST TOP PICK

Kelt Exploration(KEL-T)

Jul 17, 2019
(A Top Pick Sep 28/18, Down 55%) A liquids rich natural gas producer. It is still transitioning through 1000 sections of land in the Montney. They intent to watch development in the area and focus on best-practices in the most prolific areas.
Dennis da SilvaDennis da Silva
Owned
Unlock Rating
$3.810

Stock price when the opinion was issued

oil gas

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

WCP-T 0.22$11.05
EFX-T 0.32$15.13
CARR-N -0.08$60.31
RMD-N 1.22$274.41
FIX-N 23.91$821.62

Today's Top Picks

MSI-N -4.74$471.47
ULS-N 0.43$68.53
CECO-Q 1.64$50.53
ELF-N -2.64$137.32
NBIS-Q 7.29$106.6

Popular Articles

Latest Sell Signals

CAG-N -0.22$18.32
ACN-N 0.29$239.99
NVDA-Q 6.94$183.61
WEN-Q -0.02$9.31
ADBE-Q -1.82$364.08

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase Insights

Stockchase Insights

5i Research

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Peter Hodson

Peter Hodson

5i Research Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica